Eczema Free Forever™

Lilly/Incyte pill beats placebo in mid-stage eczema trial – Reuters


Nasdaq
Lilly/Incyte pill beats placebo in mid-stage eczema trial
Reuters
The Phase 2 eczema trial found that after 16 weeks, 61 percent of patients on the highest dose of baricitinib and a topical corticosteroid had at least a 50 percent reduction in symptoms, compared to 37 percent of patients treated with just a steroid
Olumiant improves outcomes in patients with atopic dermatitisHealio
Lilly Announces New Safety And Efficacy Data From Phase 2 Study Of BaricitinibMarkets Insider

all 5 news articles »

eczema – Google News

Eczema Free Forever™